To determine whether STAT3 and NOTCH1 signaling pathways are implicated in CD109-induced drug resistance in ovarian cancer cells, we examined the effects of STAT3 and NOTCH1 inhibitors on CD109-induced drug resistance. This evidence concerns the gene CD109 and ovarian carcinoma.